NDA 021254 · Glaxo Grp LTD
Advair Hfa
Fluticasone Propionate, Salmeterol Xinafoate · Inhalation
Last checked: Nov 20, 2026Latest source record: Aug 18, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2006
Jun 8, 2006
Approved uses
2
Original approval plus efficacy supplements
Registered trials
738
240 Phase 3, 19 recruiting
FAERS reports
60,258
34,763 serious, 3,620 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 8, 2025.
ADVAIR HFA is indicated for treatment of asthma in adult and adolescent patients aged 12 years and older. ADVAIR HFA should be used for patients not adequately controlled on a long-term asthma control medication such as an inhaled corticosteroid (ICS) or whose disease warrants initiation of treatment with both an ICS and long-acting beta 2 -adrenergic agonist (LABA). Limitations of Use ADVAIR HFA is not indicated for the relief of acute bronchospasm. ADVAIR HFA is a combination of fluticasone propionate, an inhaled corticosteroid, and salmeterol, a long-acting beta 2 ‑adrenergic agonist (LABA), indicated for treatment of asthma in adult and adolescent patients aged 12 years and older. ( 1 ) Limitations of use: Not indicated for relief of acute bronchospasm. ( 1 )
Mechanism: ADVAIR HFA ADVAIR HFA contains both fluticasone propionate and salmeterol. The mechanisms of action described below for the individual components apply to ADVAIR HFA. These drugs represent 2 different classes of medications (a synthetic corticosteroid and a LABA) that have different effects on clinical, physiologic, and inflammatory indices of asthma. Fluticasone Propionate Fluticasone propionate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. Fluticasone propionate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor that...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 19, 2012 Supplement 9 · Efficacy Pediatric Medical ReviewPediatric Clinical Pharmacology ReviewPediatric Statistical Review
- Jun 8, 2006 Original approval · Type 3 - New Dosage Form LetterReviewOther Important Information from FDA
3 products under this application
- ADVAIR HFA · FLUTICASONE PROPIONATE 0.115MG/INH; SALMETEROL XINAFOATE EQ 0.021MG BASE/INH · AEROSOL, METERED, INHALATION · Prescription
- ADVAIR HFA · FLUTICASONE PROPIONATE 0.23MG/INH; SALMETEROL XINAFOATE EQ 0.021MG BASE/INH · AEROSOL, METERED, INHALATION · Prescription
- ADVAIR HFA · FLUTICASONE PROPIONATE 0.045MG/INH; SALMETEROL XINAFOATE EQ 0.021MG BASE/INH · AEROSOL, METERED, INHALATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Fluticasone Propionate" as an intervention, any sponsor and status, largest first.
- Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01313676 · 16,568 participants · Start Jan 25, 2011 · Primary completion Jul 15, 2015
Drug: fluticasone furoate/vilanterol; fluticasone furoate and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Andalusia, Alabama; Athens, Alabama; Birmingham, Alabama · 1,611 sites in all
GlaxoSmithKlineGSK (GSK)
NCT01475721 · 11,751 participants · Start Nov 18, 2011 · Primary completion Jun 23, 2015
Drug: ADVAIR 100/50mcg; ADVAIR 250/50mcg and 4 more · For: Asthma
Sites: Athens, Alabama; Birmingham, Alabama; Florence, Alabama · 808 sites in all
- ACTIV-6: COVID-19 Study of Repurposed MedicationsPivotal-lookingCompleted
Susanna Naggie, MDAcademic, hospital or other
NCT04885530 · 10,956 participants · Start Jun 8, 2021 · Primary completion Apr 29, 2024
Drug: Ivermectin; Fluvoxamine and 3 more · For: Covid19
Sites: Chandler, Arizona; Gilbert, Arizona; Mesa, Arizona · 110 sites in all
GlaxoSmithKlineGSK (GSK)
NCT02164513 · 10,355 participants · Start Jun 30, 2014 · Primary completion Jul 17, 2017
Drug: fluticasone furoate (FF); vilanterol (VI) and 1 more · For: Pulmonary Disease, Chronic Obstructive
Sites: Athens, Alabama; Birmingham, Alabama; Florence, Alabama · 998 sites in all
- 6-month Safety and Benefit Study of ADVAIR in Children 4-11 Years OldPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01462344 · 6,250 participants · Start Nov 17, 2011 · Primary completion Nov 1, 2015
Drug: ADVAIR 100/50mcg; ADVAIR 250/50mcg and 2 more · For: Asthma
Sites: Birmingham, Alabama; Mobile, Alabama; Montgomery, Alabama · 530 sites in all
- Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00268216 · 6,228 participants · Start Sep 2000 · Primary completion Nov 2005
Drug: Salmeterol 50mcg/ Fluticasone Propionate 500mcg · For: Pulmonary Disease, Chronic Obstructive
Sites: Birmingham, Alabama; Jasper, Alabama; Mobile, Alabama · 459 sites in all
- An Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in AsthmaPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT01706198 · 4,233 participants · Start Nov 1, 2012 · Primary completion Dec 1, 2016
Drug: fluticasone furoate + vilanterol; inhaled corticosteroid with or without a long acting beta2-agonist · For: Asthma
Sites: Altrincham, United Kingdom; Bowdon, United Kingdom; Cheadle, United Kingdom · 180 sites in all
- QVA vs. Salmeterol/Fluticasone, 52-week Exacerbation Study, FLAME (EFfect of Indacaterol Glycopyronium Vs Fluticasone Salmeterol on COPD Exacerbations)Pivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT01782326 · 3,362 participants · Start Jul 2013 · Primary completion Sep 2015
Drug: QVA149; Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS) · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Ciudad de Buenos Aires, Argentina; Buenos Aires, Argentina; Caba, Argentina · 499 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- dyspnoea10,067
- asthma8,223
- drug ineffective5,535
- pneumonia4,989
- cough4,984
- wheezing4,239
- fatigue3,968
- headache3,663
- malaise3,642
- pain3,429
- off label use2,872
- nausea2,761
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 584 |
| 2005 | 50 |
| 2006 | 1,754 |
| 2007 | 36 |
| 2008 | 479 |
| 2009 | 1,711 |
| 2010 | 106 |
| 2011 | 388 |
| 2012 | 449 |
| 2013 | 684 |
| 2014 | 6,553 |
| 2015 | 5,812 |
| 2016 | 6,163 |
| 2017 | 4,592 |
| 2018 | 4,515 |
| 2019 | 4,884 |
| 2020 | 4,812 |
| 2021 | 3,556 |
| 2022 | 2,972 |
| 2023 | 2,761 |
| 2024 | 3,075 |
| 2025 | 2,642 |
| 2026 | 1,678 |
Recalls
2 FDA enforcement reports for this application.
Oct 24, 2012 · Class III · Terminated
Product Lacks Stability: These lots are being recalled due to the failure to meet the particle size distribution specification.
Oct 24, 2012 · Class III · Terminated
Product Lacks Stability: These lots are being recalled due to the failure to meet the particle size distribution specification.
Shortages
FDA's drug shortage list.
To Be Discontinued · updated Jul 27, 2026
Advair HFA, Aerosol, Metered, 230 ug; 21 ug (NDC 0173-0717-22). The anticipated date that GSK will cease distribution of the presentation is approximately December 31, 2026. The 120 dose presentation of this product...
To Be Discontinued · updated Jul 27, 2026
Advair HFA, Aerosol, Metered, 115 ug; 21 ug (NDC 0173-0716-22). The anticipated date that GSK will cease distribution of the presentation is approximately December 31, 2026. The 120 dose presentation of this product...
To Be Discontinued · updated Jul 27, 2026
Advair HFA, Aerosol, Metered, 45 ug; 21 ug (NDC 0173-0715-22). The anticipated date that GSK will cease distribution of the presentation is approximately December 31, 2026. The 120 dose presentation of this product...
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Advair HFA (Fluticasone Propion/Salmeterol)
2024 spending
$321M
Beneficiaries
200,081
715,505 claims
Per beneficiary
$1,602
$28.71 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $313,758,155 |
| 2021 | $346,301,512 |
| 2022 | $384,716,839 |
| 2023 | $398,376,288 |
| 2024 | $320,587,780 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Intranasal antihistamines and corticosteroids in allergic rhinitis: A systematic review and meta-analysis.
Sousa-Pinto B, Vieira RJ, Brozek J, et al. · J Allergy Clin Immunol 2024 · Systematic Review, Meta-Analysis
- Oral steroid-sparing effect of high-dose inhaled corticosteroids in asthma.
Maijers I, Kearns N, Harper J, et al. · Eur Respir J 2020 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis.
Lipworth BJ · Arch Intern Med 1999 · Meta-Analysis, Systematic Review
- Fluticasone Propionate Orally Disintegrating Tablet (APT-1011) for Eosinophilic Esophagitis: Randomized Controlled Trial.
Dellon ES, Lucendo AJ, Schlag C, et al. · Clin Gastroenterol Hepatol 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Quantitative comparison of dose-effect and time-course of fluticasone furoate and fluticasone propionate in adult and adolescent patients with persistent asthma: A systematic review and meta-analysis.
Zhong Y, Li L, Chen R, et al. · Respirology 2022 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Inhaled fluticasone propionate and adrenal effects in adult asthma: systematic review and meta-analysis.
Masoli M, Weatherall M, Holt S, et al. · Eur Respir J 2006 · Meta-Analysis, Research Support, Non-U.S. Gov't
Sponsor: GSK
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.